EQ News & Events

Equillium appointed Snehal Naik as chief development officer. Naik will lead clinical development and medical strategy across Equillium's pipeline, with responsibility for advancing EQ504 into the clinic and progressing future programs. Most recently, Naik served as senior VP and head of clinical development at Ventyx Biosciences.

"Following our March year-end update and financing, we have remained focused on advancing EQ504 toward the clinic while continuing to expand the scientific foundation supporting its differentiated profile," said Bruce Steel, CEO of Equillium. "Recent preclinical data presented at IMMUNOLOGY2026 further strengthen our growing body of evidence for EQ504's ability to modulate immune responses while promoting epithelial repair and barrier restoration. We believe these attributes reinforce the potential of EQ504 as a potentially differentiated, non-immunosuppressive therapeutic approach in ulcerative colitis and other inflammatory diseases."